<DOC>
	<DOCNO>NCT03097120</DOCNO>
	<brief_summary>Background : Heart disease major cause illness death woman . To understand good role estrogen treatment prevention heart disease , information need effect coronary atherosclerosis extent concomitant progestin therapy may modify effect . Methods : The investigator randomly assign total 309 woman angiographically verify coronary disease receive 0.625 mg conjugate estrogen per day , 0.625 mg conjugate estrogen plus 2.5 mg medroxyprogesterone acetate per day , placebo . The woman follow mean ( ±SD ) 3.2±0.6 year . Base-line follow-up coronary angiogram analyze quantitative method . Follow-up coronary angiogram obtain average 3.2 year follow .</brief_summary>
	<brief_title>The Estrogen Replacement Atherosclerosis Trial ; Primary Outcome Measure Mean Minimal Coronary Artery Diameter After Avg 3.2 Yrs .</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>postmenopausal currently receive estrogenreplacement treatment one epicardial coronary stenosis least 30 percent luminal diameter , measure quantitative coronary angiography know suspect breast endometrial carcinoma previous plan coronaryartery bypass surgery , history deepvein thrombosis pulmonary embolism , symptomatic gallstone , serum aspartate aminotransferase level 1.5 time normal value , fast triglyceride level 400 mg per deciliter serum creatinine level 2.0 mg per deciliter 70 percent stenosis leave main coronary artery , uncontrolled hypertension , uncontrolled diabetes .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>